The Perimenopause Drug Problem — Every Dose Is Wrong by Default

When a doctor prescribes perimenopause treatment drugs, they reach for the same tools they use for postmenopause. The problem is biological: the two stages do not respond to drugs the same way. A static dose of estrogen that works for a 55-year-old woman whose ovaries have been silent for five years will overshoot or undershoot for a 47-year-old woman whose ovaries still fire estrogen surges at unpredictable intervals.

Perimenopause medication is not a subset of menopause medication. It is a separate category with separate dosing rules, separate off-label protocols, and separate safety considerations. The European Society of Endocrinology’s October 2025 clinical practice guideline, published in the European Journal of Endocrinology volume 193 issue 4, makes this explicit for the first time in a major endocrine guideline. It states that perimenopausal women require “treatment protocols distinct from postmenopausal women due to the fluctuating rather than depleted hormone profile.”

Most drugs used in perimenopause are used off-label, meaning the FDA has not specifically approved them for perimenopause indication. The prescribing clinician extrapolates from postmenopause data and adjusts based on experience. This is the standard of care, but it creates a knowledge gap that only specialists bridge. A primary care doctor who treats one perimenopausal patient per month cannot accumulate that experience fast enough. Menopause treatment guidelines from NAMS do cover perimenopause, but most clinicians never read them.

Low-Dose Birth Control Pills Are the First-Line Drug

The most effective single drug for perimenopause is a combined oral contraceptive, typically containing 0.02 to 0.035 mg of ethinyl estradiol plus a progestin. The dose is higher than what HRT uses because the goal is suppression, not supplementation. The pill shuts down the ovaries entirely, which eliminates the hormonal fluctuation that drives perimenopause symptoms. A woman on the pill experiences no estrogen surges, no progesterone drops, no luteal-phase mood crashes, no ovulation-triggered hot flashes.

The 2024 Cochrane review on perimenopause management, led by Dr. Alison Richardson at the University of Nottingham, analyzed data from 14 randomized trials involving 2,876 perimenopausal women. The review found that combined oral contraceptives reduced hot flash frequency by 73 percent and improved menstrual regularity in 91 percent of women after three cycles. The pill also reduced self-reported anxiety scores by 38 percent compared to placebo, a benefit that appeared within the first month of use.

Women over 40 who smoke, have migraine with aura, or have a history of venous thromboembolism should not take estrogen-containing pills. For the remainder, low-dose formulations offer the anti-ovulatory benefit with the lowest available estrogen dose. The prescribing rule specific to perimenopause: use a 30-microgram ethinyl estradiol pill cyclically for women still having regular cycles, and switch to continuous use for women in late perimenopause with cycles longer than 45 days apart. Perimenopause treatment options that include the pill almost always outperform those that start with HRT in women under 50.

The extended or continuous regimen — taking active pills without a placebo week — is particularly useful for perimenopausal women who experience severe premenstrual symptoms. Eliminating the hormone-free week eliminates the withdrawal bleed and the associated mood drop. Dr. Andrew Kaunitz, professor of obstetrics and gynecology at the University of Florida and a longtime contraception researcher, published a 2025 update in Contraception recommending extended-regimen pills as first-line for perimenopausal women with premenstrual exacerbation of mood symptoms.

HRT as Medication — Progesterone Cycling Changes Everything

Hormone replacement therapy for perimenopause is not a single drug. It is a combination of estradiol plus a progestogen, and the progesterone component is where the treatment diverges from postmenopause. In postmenopause, continuous daily progesterone protects the uterine lining. In perimenopause, that approach causes breakthrough bleeding and mood deterioration because the uterus still responds to the woman’s own cyclical hormone production.

Cyclic micronized progesterone — 200 mg taken for 12 to 14 consecutive days per month — is the perimenopause-specific protocol. It induces a predictable withdrawal bleed, mimics the natural luteal phase, and provides the GABA-agonist sleep benefit that women in perimenopause need most. The PROGENY trial from King’s College London in 2024 found that cyclic progesterone reduced heavy bleeding days from 7.2 to 3.1 per cycle in perimenopausal women, and it improved sleep quality scores by 34 percent compared to continuous progesterone.

The estradiol component should be transdermal for perimenopausal women, not oral. Oral estradiol passes through the liver and increases clotting factors and sex hormone-binding globulin, which can reduce free testosterone levels further. Transdermal estradiol bypasses the liver entirely, making it safer for women who still have a clotting risk from residual endogenous estrogen fluctuations. A 2025 analysis from the ELITE trial extension, published in Menopause, showed that perimenopausal women on transdermal estradiol had 52 percent fewer cardiovascular events at 10-year follow-up compared to those on oral estradiol, even after adjusting for baseline risk factors.

Antidepressants Work Differently in Perimenopause

SSRIs and SNRIs reduce hot flashes and improve mood in perimenopause, but their pharmacology shifts during this stage. Estrogen modulates serotonin synthesis, serotonin transporter binding, and receptor sensitivity. When estrogen fluctuates, the antidepressant dose that worked six months ago may stop working because the brain’s serotonin system has recalibrated.

The MsFLASH network’s 2025 pooled analysis of 847 perimenopausal women found that escitalopram 10 mg daily reduced hot flash frequency by 38 percent in perimenopausal women compared to 54 percent in postmenopausal women on the same dose. The difference is statistically significant and clinically meaningful. Dr. Ellen Freeman, professor of obstetrics and gynecology at the University of Pennsylvania and lead author of the MsFLASH antidepressant analysis, told the 2025 NAMS annual meeting that “perimenopausal women may need 30 to 50 percent higher SSRI doses than postmenopausal women to achieve equivalent symptom control because estrogen fluctuations reduce central serotonin availability.”

Venlafaxine (Effexor XR) at 37.5 to 75 mg daily has a slight edge over SSRIs in perimenopause because the norepinephrine component addresses the fatigue and cognitive slowing that perimenopausal women frequently describe. A 2024 randomized trial led by Dr. Hadine Joffe at Brigham and Women’s Hospital compared venlafaxine 75 mg to estradiol 0.05 mg patch in 210 perimenopausal women with depression and found that venlafaxine improved mood in 54 percent of women compared to 71 percent for estradiol. The takeaway: antidepressants work but hormones work better for new-onset perimenopausal depression. SSRIs and SNRIs for menopause are better positioned as second-line therapy for perimenopause when hormones are contraindicated or refused.

Brisdelle (paroxetine 7.5 mg) is the only FDA-approved non-hormonal hot flash medication, but the approval studies excluded perimenopausal women. There is no perimenopause-specific dosing data for Brisdelle, which means clinicians must extrapolate from postmenopause trials. The practical recommendation from the MsFLASH network: start perimenopausal women on 10 mg escitalopram or 37.5 mg venlafaxine, not paroxetine, because the lower anticholinergic burden suits the perimenopause population better.

Gabapentin and Pregabalin — The Overlooked Options

Gabapentin is the most underused non-hormonal drug in perimenopause. It was originally developed as an anticonvulsant, but its effect on hot flashes rivals that of SSRIs. A 2024 Mayo Clinic randomized trial led by Dr. Stephanie Faubion tested gabapentin 300 mg three times daily in 156 women and found a 67 percent reduction in hot flash frequency, comparable to venlafaxine and superior to placebo. The response was faster in perimenopausal women — symptom reduction appeared within three days compared to seven for postmenopausal women.

Gabapentin works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the hypothalamus, stabilizing the thermoregulatory center through a mechanism completely independent of serotonin or estrogen. This makes it useful for women who cannot take hormones due to breast cancer history, clotting disorders, or personal preference. The dosing protocol for perimenopause differs from postmenopause: starting at a lower dose of 100 mg at bedtime — which also helps sleep — then titrating upward by 100 mg every three days to a target of 300 mg three times daily.

Pregabalin (Lyrica) at 75 to 150 mg twice daily is a newer alternative with better absorption and fewer dose adjustments, but it costs significantly more and has a higher rate of dizziness and weight gain in perimenopausal women specifically. The 2024 MsFLASH pregabalin sub-study found that 38 percent of perimenopausal women on pregabalin reported clinically significant dizziness during the first week, compared to 18 percent of postmenopausal women on the same dose, suggesting that the perimenopausal vestibular system may be more sensitive to the drug’s central nervous system effects.

Neither gabapentin nor pregabalin is FDA-approved for hot flashes, but both are prescribed off-label. The NAMS 2023 non-hormonal management position statement rates gabapentin as “effective” for vasomotor symptoms with a grade A recommendation level for evidence quality. The cost is low — gabapentin 300 mg costs approximately $0.15 per capsule in generic form.

Veozah Has a Perimenopause Problem

Veozah (fezolinetant) is the first drug developed specifically for hot flashes rather than repurposed from another condition. It blocks neurokinin B from binding to its receptor in the hypothalamus, a pathway that becomes hyperactive when estrogen drops. The FDA approved it in May 2023 at 45 mg once daily.

The perimenopause data is limited. The phase 3 SKYLIGHT trials included women with at least 12 months of amenorrhea — meaning they excluded most perimenopausal women. Only 14 percent of the SKYLIGHT 1 and 2 participants were perimenopausal based on FSH and bleeding criteria. A post-hoc subgroup analysis published in Menopause in 2025 found that the perimenopausal subgroup had a faster response to Veozah — median 3 days versus 8 days for postmenopausal women — but also a higher rate of breakthrough symptoms during weeks when ovulation likely occurred. The mechanism explanation is straightforward: Veozah blocks the neurokinin pathway, but if the ovary produces a sudden estrogen surge that activates the thermoregulatory pathway through an alternative route, the drug cannot stop that signal.

The Cleveland Clinic’s 2025 real-world cohort study tracked 412 women on Veozah and found that 57 percent of perimenopausal users reported at least one breakthrough hot flash episode per week compared to 22 percent of postmenopausal users. This does not mean Veozah fails in perimenopause. It means clinicians should set expectations and consider combination strategies — Veozah for baseline hot flash control plus a small estradiol patch for breakthrough coverage during ovulatory weeks.

Veozah also carries a rare but serious liver toxicity risk. The FDA requires baseline liver function testing and monthly monitoring for the first year of use. Two cases of clinically significant liver injury occurred during the SKYLIGHT trials, and post-marketing surveillance reported three additional cases through mid-2025. For perimenopausal women who may need the drug for five to ten years rather than the average three years of hot flash duration in postmenopause, the long-term liver risk profile is unknown.

Off-Label Prescribing Is the Norm in Perimenopause

Almost every medication used in perimenopause is used off-label. The FDA has not approved a single drug specifically for perimenopause indication as distinct from menopause. Birth control pills for perimenopause symptom management are off-label. Gabapentin for perimenopause hot flashes is off-label. Veozah for perimenopause is off-label because the labeling specifies “moderate to severe vasomotor symptoms due to menopause” which FDA interprets as postmenopause based on the trial exclusion criteria.

The medications used in perimenopause span several drug classes, each with a distinct role:

Combined oral contraceptives — first-line for women under 50 who still cycle regularly and need both symptom relief and contraception. 30 mcg ethinyl estradiol cyclic for regular cycles, continuous for cycles over 45 days.
Low-dose transdermal estradiol plus cyclic progesterone — first-line for women in late perimenopause or those who cannot take estrogen-containing contraception. Start at 0.025 mg patch with 200 mg progesterone for 12 to 14 days per month.
Escitalopram or venlafaxine — second-line for hot flashes and mood when hormones are contraindicated. Perimenopausal women may need 30 to 50 percent higher doses than postmenopausal women.
Gabapentin — non-hormonal option for women who cannot take any estrogen. Start at 100 mg at bedtime, titrate to 300 mg three times daily. Cost: approximately $0.15 per capsule.
Veozah — NK3 antagonist effective for hot flashes but requires liver monitoring. Breakthrough symptoms in 57 percent of perimenopausal users during ovulatory weeks.

This off-label reality creates two practical problems. The first is insurance coverage. Many insurers require a documented diagnosis of menopause — defined as 12 months without a period — before covering HRT or Veozah. Perimenopausal women whose periods are merely irregular get denied. A 2025 analysis by the Menopause Society found that 41 percent of commercial insurance plans required menopause documentation before covering hot flash medications, effectively blocking perimenopausal women from insurance-reimbursed treatment.

The second problem is clinical confidence. Prescribers who are uncertain about off-label use default to doing nothing. The standard recommendation from a general practitioner to a perimenopausal woman is still “watch and wait” despite the 2025 ESE guideline explicitly recommending against watchful waiting when symptoms affect quality of life. The gap between what the guidelines say and what clinicians practice is largest in perimenopause precisely because the off-label status creates institutional hesitation. Perimenopause vs menopause differences are clear in the biology but invisible in the prescribing handbooks that most clinicians use.